Pacific Biosciences of California, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Pacific Biosciences of California, Inc. (PACB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$137.51 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-02-28
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$31.76M, a 103.73% decline year-over-year.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $850.79M, a 2068.44% increase year-over-year.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $39.23M, a 102.65% increase year-over-year.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $19.36M, a 116.30% increase year-over-year.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$137.51M, a 136.20% decline from fiscal 2021.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $379.87M, a 630.24% increase from fiscal 2020.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $52.02M, a 405.88% increase from fiscal 2019.
- Pacific Biosciences of California, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $10.28M, a 340.01% increase from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$137.51M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$158.16M 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | -$152.15M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$31.76M 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $379.87M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $344.50M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $377.15M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $850.79M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $52.02M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $38.90M 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $13.21M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $39.23M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $10.28M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $13.74M 10-Q · filed 2020-11-03 | |||
| 2019-06-30 | $11.01M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $19.36M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $2.34M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $21.56M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $6.55M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $8.95M 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | -$258.00K 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $9.17M 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | $19.71M 10-Q · filed 2018-08-03 | |||
| 2017-03-31 | $12.22M 10-Q · filed 2018-05-02 | |||
| 2016-12-31 | -$16.86M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |